HA方案治疗CML—CP的临床研究  

Clinical study of combination chemotherapy regimen homoharringtonine and cytarabine for the curative effect on CML in chronic phase

作　　者：孙爱红[1] 何斌[1] 孙梅[1] 汪中强[1] 顾健[1] 

机构地区：[1]扬州大学临床医学/江苏省苏北人民医院血液科,225001

出　　处：《中国临床实用医学》2009年第8期51-52,共2页China Clinical Practical Medicine

摘　　要：目的观察HA联合化疗方案对慢性粒细胞白血病慢性期（CML-CP）的临床疗效和副作用。方法选择36例初诊CML—CP患者，化疗方案为HA联合化疗5—7d，其中高三尖杉酯碱（HHT）5mg／d，阿糖胞苷（Ara-C）200mg／d。主要观察外周血白细胞数、脾脏大小、染色体及化疗副作用。结果HA化疗方案治疗CML—CP近期血液学完全缓解率55．56％，有效率91．67％；近期观察细胞遗传学未发现变化；副作用可以耐受，但是7dHA化疗方案后骨髓抑制发生率高。结论HA化疗方案对于CML—CP近期有肯定疗效，是不能行allo—BMT或者imatinib治疗的有效治疗方法。Objective To study the efficacy and adverse effects of combination chemotherapy regimen including homoharringtonine and eytarabine in the treatment of chronic-phase of chronic myelogenous leukemia. Methods Thirty-six cases of chronic-phase chronic myelogenous leukemia had received 5 days or 7 days course of combination chemotherapy regimen homoharringtonine and cytarabine. Their spleen size, cytogenetic responses and adverse effects were observed. Results The complete remission（CR） rate studied was 50. 0% and 61.1% in 5 days＇ and 7 days＇ treated groups. The incidence of severe bonemarrow depression in 7 days＇ group（ 16. 7% ） was higher than that in 5 days＇ group（0. 0% ） （P 〈0. 05）. Conclusion The combination chemotherapy HA regimen had curative effects in chronic-phase chronic myelogenous leukemia therapy while the incidence of severe bonemarrow depression in 7 days＇ group（ 16. 7% ） was higher than that in 5 days＇ group（P 〈0. 05）.

关 键 词：慢性粒细胞白血病慢性期(CML-CP) HA方案 临床疗效 

分 类 号：R733.72[医药卫生—肿瘤]